AinosAIMD
AIMD
About: Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
Employees: 44
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
60% more capital invested
Capital invested by funds: $34.5K [Q4 2024] → $55.3K (+$20.8K) [Q1 2025]
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
33% more funds holding
Funds holding: 9 [Q4 2024] → 12 (+3) [Q1 2025]
0.19% more ownership
Funds ownership: 0.54% [Q4 2024] → 0.73% (+0.19%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for AIMD.
Financial journalist opinion
Based on 8 articles about AIMD published over the past 30 days
Neutral
Accesswire
1 day ago
Water Tower Research Highlights Growing Momentum for Ainos' Scent-Tech Solutions and Industrial SmellTech Leadership with New High-Impact Partnerships
Ainos Pioneers SmellTech as the Next Sensory Frontier in Industrial AI 2H 2025 Industrial Pilots and Subscription Model Poised to Unlock Multi-Million Dollar Revenue Potential in 2026 SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 10, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent detection, today announced that Water Tower Research ("WTR") has published a new report spotlighting Ainos' rapid commercial acceleration in industrial AI through its AI Nose. The report highlights a wave of high-impact partnerships, positioning AI Nose as an emerging digital olfaction platform across mission-critical industrial environments.
Neutral
Accesswire
4 days ago
Ainos and Solomon Partner to Bring SmellTech Across Asia's Industrial Landscape
AI Nose and Smell Language Model Combine with Solomon's Vision AI to Power Multi-Sensory Automation Partnership Accelerates AI Scent Intelligence Deployment in Semiconductors, Robotics and More SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 7, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent detection, today announced a five-year distribution partnership with Solomon Technology Corporation, a leader in machine vision, industrial AI, and smart automation. The partnership aims to fast-track Ainos' AI Nose platform into Asia's key manufacturing sectors: semiconductors, petrochemicals, autonomous mobile robots (AMRs), and more.
Neutral
Accesswire
1 week ago
Ainos Completes Stock Consolidation, Enters New Phase of Global Expansion and Technology Commercialization
Partners With ASE to Scale AI Nose Deployment and Set New Standard in Intelligent Sensing Achieves Strategic Inflection Point in 1H 2025 with Partnerships and Operational Breakthroughs SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced the completion of a 1-for-5 stock consolidation, effective at the opening of trading on June 30, 2025. The move strengthens the Company's capital structure, aligns with Nasdaq listing requirements, and positions Ainos to scale global commercial operations across its AI Nose platforms.
Neutral
Accesswire
2 weeks ago
Ainos and ASE Technology Holding Broaden Strategic Partnership to Target Deploy Up to 15,000 AI Nose Across Key Sites
Relationship Broadens Scope to Key ASE and SPIL Facilities with Multi-Phase Deployment Milestone Positions ASEH and Ainos as First-Mover in AI-Powered Scent Intelligence for the Semiconductor Industry SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 27, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") , a leader in AI-driven scent digitization, today announced the expansion of its strategic relationship with ASE Technology Holding Co., Ltd. ("ASEH", TWSE: 3711, NYSE: ASX), the world's leading provider of semiconductor assembly and test services.
Neutral
Accesswire
2 weeks ago
Ainos Aligns Capital Structure With 2H 2025 Execution Roadmap; Announces Stock Consolidation
SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 26, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it will implement a consolidation of its common stock ("stock consolidation"), effective at the opening of trading on June 30, 2025. This strategic action positions Ainos to attract broader institutional interest as it enters a commercial execution phase in the second half of 2025 and supports the Company's continued Nasdaq listing.
Neutral
Accesswire
2 weeks ago
Ainos and Kenmec Launch Strategic Partnership to Deploy AI-Powered Scent Intelligence in Smart Factories Across Asia
AI Nose and SLM SmellTech platform enter scale-up phase targeting robotics, automation, and environmental sensing markets Kenmec and Ainos to show case AI Nose and SLM in Automation Taipei 2025 in August SAN DIEGO, CA / ACCESS Newswire / June 24, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-driven scent digitization, today announced it has formed a legally binding strategic partnership with Kenmec Mechanical Engineering Co., Ltd. ("Kenmec"), a Taiwanese public listed leader in automation and system integration.
Neutral
Accesswire
3 weeks ago
Water Tower Research Spotlights Ainos' Advances and Milestones in Digital Olfaction and Healthcare: Entering Inflection Point in 2H25
Ainos Hits Inflection Point with AI Nose Pilot Ramp in Senior Care, Robotics, and Semiconductors Key VELDONA® Human Clinical Studies Secure Taiwan Regulatory Greenlight, Accelerating Development SAN DIEGO, CA / ACCESS Newswire / June 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting Ainos' critical milestones and strategic advancements in 1H25, and its robust roadmap for the remainder of the year, with multiple large scale AI Nose pilot programs and Veldona ® clinical trials on deck. Key Highlights from the Report: Breakthroughs in accuracy and revenues demonstrate senior care market readiness: AI Nose achieved an 85% accuracy rate in hygiene monitoring, exceeding a performance target of 80%.
Neutral
Accesswire
3 weeks ago
Ainos Issues Mid-Year Update: Reaching Strategic Inflection in SmellTech and Immunotherapy
AI Nose Platform Advances Toward Scaled Pilot Programs Across Healthcare, Robotics, and Industrials VELDONA® Oral Interferon Receives Approval to Begin Human Trials in Taiwan SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today issued a mid-year update outlining key strategic milestones achieved during the first half of 2025. The Company has transitioned from R&D to commercial execution, marked by its first AI Nose-driven revenue, expanded industry partnerships, and regulatory approval for its lead VELDONA human drug candidates to enter clinical trials.
Neutral
Accesswire
1 month ago
Water Tower Research Highlights Ainos' AI Nose Accuracy Breakthrough in Elderly Care Monitoring: SmellTech Gets Smarter
AI Nose accuracy in elderly care improved to 85% with additional Smell ID training AI-friendly healthcare policies to provide tailwinds for commercial rollout SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 3, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting a significant milestone in the Company's AI Nose project for elderly care. AI Nose has reached approximately 85% accuracy in excretion odor detection-improving over the recently met internal milestone of 80%.
Neutral
Accesswire
1 month ago
Ainos AI Nose Improves Accuracy in Hygiene Monitoring To 85% from 80%
Accelerating Toward Commercial Rollout as AI Nose Solves Critical Gaps in Elder Care SAN DIEGO, CA / ACCESS Newswire / May 29, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, announced today that its proprietary AI Nose platform achieved approximately 85% accuracy in detecting excretion odors data, an improvement from 80% previously, based on collected from 254 participant instances in Japan and Taiwan, resulting in 2119 valid entries for subsequent statistical evaluation. The milestone validates AI Nose as a deploy able solution for non-contact hygiene monitoring in long-term care (LTC) and positions Ainos to lead the emerging SmellTech category.
Charts implemented using Lightweight Charts™